Sponsor:
Vergent Bioscience, Inc.
Code:
NCT07499674
Conditions
Lung Cancer
Lung Metastases
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Abenacianine
Near Infrared (NIR) Imaging
Brief summary:
Conditions
Lung Cancer
Lung Metastases
Study ID
NCT07499674
Start date
Mar 31, 2026
Status verified date
Aug, 2026
Completion date
Mar, 2027
Anticipated
Primary completion date
Dec, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
132 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
other: Abenacianine with surgery using Standard of Care (SOC) only
other: Abenacianine with surgery using Standard of Care plus Near infrared (NIR) imaging
Interventions
Abenacianine
Near Infrared (NIR) Imaging
Primary outcome measure
Central contacts
Locations
City of Hope National Medical Center
Recruiting
Duarte, California, United States, 91010
University of Colorado Hospital
Recruiting
Aurora, Colorado, United States, 80045
Orlando Health Cancer Center
Recruiting
Orlando, Florida, United States, 32806
University of Michigan
Recruiting
Ann Arbor, Michigan, United States, 48109
Mayo Clinic
Recruiting
Rochester, Minnesota, United States, 55905
Hospital of the University of Pennsylvania
Recruiting
Philadelphia, Pennsylvania, United States, 19104
University of Texas, MD Anderson Cancer Center
Recruiting
Houston, Texas, United States, 77030
Sponsor
Vergent Bioscience, Inc.
Last update posted
Aug 19, 2026
Last verified
Aug, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Vergent Bioscience, Inc. on 2026-08-19.